Europe’s biggest drug company has announced it is taking the first steps towards marketing a vaccine in Africa from which it never expects to make money. GlaxoSmithKline says it has begun filing documents with the regulatory authorities concerning its meningitis vaccine called Globorix
Share this Story
RSS – Posts